Health

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

Supported by GlaxoSmithKline. The Ellipta brand of inhalers is owned by or licensed to the GlaxoSmithKline group of companies.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Lipson, Dr. Brealey, Ms. Brooks, Dr. Day, Dr. Jones, Ms. Kilbride, and Dr. Pascoe report being employed by and being a shareholder in GlaxoSmithKline; Dr. Barnhart, being employed by and holding stock options in GlaxoSmithKline; Dr. Dransfield, receiving consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, PneumRx/BTG, Boston Scientific, Novartis, and GlaxoSmithKline; Dr. Halpin, receiving honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Pfizer, Sandoz, and GlaxoSmithKline; Dr. Han, receiving consulting fees from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline and research support from Novartis and Sunovion Pharmaceuticals; Dr. Lange, receiving advisory board fees from GlaxoSmithKline; Dr. Lomas, receiving fees for serving as chair of the GlaxoSmithKline Respiratory Therapy Area Board and advisory board fees from GlaxoSmithKline; Dr. Martinez, receiving advisory board fees and fees for serving on a steering committee from AstraZeneca and GlaxoSmithKline, fees for serving on a steering committee from Boehringer Ingelheim, consulting fees from ProterixBio, fees for serving on a data and safety monitoring board from Genentech, advisory board fees and fees for a global disease state presentation from Novartis, advisory board fees from Pearl Therapeutics, and fees for continuing medical education from UpToDate; Dr. Singh, receiving consulting fees from Apellis Pharmaceuticals, Cipla, Genentech, Peptinnovate, and Sky Pharma and grant support and consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark Pharmaceuticals, Menarini, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva Pharmaceuticals, Theravance Biopharma, and Verona Pharma; Ms. Tabberer, being employed by and holding stock in GlaxoSmithKline; and Dr. Wise, receiving grant support and fees for serving on an advisory committee from GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported.

This article was published on April 18, 2018, at NEJM.org.

We thank the patients, families, and investigators around the world who participated in the IMPACT trial, without whose help this trial could not have been possible; current and former GlaxoSmithKline study team members (Nicholas Locantore for the original statistical work and trial design; Helen Barnacle for assistance in trial design; Michelle Fry [data quality lead]; Pam Manchester, Jill Wolford, Irene Shupe, Igor Moshenin, Soo-Yeon Chung, Tammy Kitaoka, Oliver Kante, and Suhel Patel [operational support]; Suhas Ravindra [programming]; and Morrys Kaisermann, Anya Harry, Jonathan Steinfeld, Cindy Liu, Catriona Crawford, and Rajat Mohindra [medical monitoring and pharmacovigilance]); the staff of Veramed for support with statistical analyses; Sally Kilbride and Jean Brooks (GlaxoSmithKline) for oversight of the data analysis; and Catherine Amey and Catherine Elliott of Gardiner-Caldwell Communications (Macclesfield, United Kingdom) for medical-writing support.


Source link
Back to top button
close
Thanks !

Thanks for sharing this, you are awesome !

Pin It on Pinterest

Share This

Share this post with your friends!